137 related articles for article (PubMed ID: 12451985)
1. Nucleotide excision repair protein levels vis-à-vis anticancer drug resistance in 60 human tumor cell lines.
Chen ZP; Malapetsa A; Monks A; Myers TG; Mohr G; Sausville EA; Scudiero DA; Panasci LC
Ai Zheng; 2002 Mar; 21(3):233-9. PubMed ID: 12451985
[TBL] [Abstract][Full Text] [Related]
2. DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program.
Xu Z; Chen ZP; Malapetsa A; Alaoui-Jamali M; Bergeron J; Monks A; Myers TG; Mohr G; Sausville EA; Scudiero DA; Aloyz R; Panasci LC
Anticancer Drugs; 2002 Jun; 13(5):511-9. PubMed ID: 12045463
[TBL] [Abstract][Full Text] [Related]
3. Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD.
Aloyz R; Xu ZY; Bello V; Bergeron J; Han FY; Yan Y; Malapetsa A; Alaoui-Jamali MA; Duncan AM; Panasci L
Cancer Res; 2002 Oct; 62(19):5457-62. PubMed ID: 12359753
[TBL] [Abstract][Full Text] [Related]
4. Extraneuronal monoamine transporter expression and DNA repair vis-à-vis 2-chloroethyl-3-sarcosinamide-1-nitrosourea cytotoxicity in human tumor cell lines.
Chen ZP; Remack J; Brent TP; Mohr G; Panasci LC
Clin Cancer Res; 1999 Dec; 5(12):4186-90. PubMed ID: 10632359
[TBL] [Abstract][Full Text] [Related]
5. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells.
Koeppel F; Poindessous V; Lazar V; Raymond E; Sarasin A; Larsen AK
Clin Cancer Res; 2004 Aug; 10(16):5604-13. PubMed ID: 15328203
[TBL] [Abstract][Full Text] [Related]
6. Enhancing alkylating agent resistance through ERCC2 gene transfection in human glioma cell line.
Chen Z; Zhang J; Mohr G
Chin Med J (Engl); 2003 Aug; 116(8):1171-4. PubMed ID: 12935404
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of open complex and dual incision formation by human nucleotide excision repair factors.
Evans E; Moggs JG; Hwang JR; Egly JM; Wood RD
EMBO J; 1997 Nov; 16(21):6559-73. PubMed ID: 9351836
[TBL] [Abstract][Full Text] [Related]
8. Regulation of DNA repair gene expression in human cancer cell lines.
McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
[TBL] [Abstract][Full Text] [Related]
9. [Enhancement effect of nucleotide excision repair gene xeroderma pigmentosun group a antisense RNA on sensitivity of human lung adenocarcinoma cell line A549 to cisplatin].
Fan W; Zhang HL; Wu XM
Ai Zheng; 2005 Apr; 24(4):403-7. PubMed ID: 15820060
[TBL] [Abstract][Full Text] [Related]
10. XPA protein as a limiting factor for nucleotide excision repair and UV sensitivity in human cells.
Köberle B; Roginskaya V; Wood RD
DNA Repair (Amst); 2006 May; 5(5):641-8. PubMed ID: 16413230
[TBL] [Abstract][Full Text] [Related]
11. Excision repair cross complementing-group 1: gene expression and platinum resistance.
Altaha R; Liang X; Yu JJ; Reed E
Int J Mol Med; 2004 Dec; 14(6):959-70. PubMed ID: 15547660
[TBL] [Abstract][Full Text] [Related]
12. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
[TBL] [Abstract][Full Text] [Related]
13. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins.
Jiang H; Yang LY
Cancer Res; 1999 Sep; 59(18):4529-34. PubMed ID: 10493501
[TBL] [Abstract][Full Text] [Related]
14. Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2.
Dabholkar MD; Berger MS; Vionnet JA; Egwuagu C; Silber JR; Yu JJ; Reed E
Cancer Res; 1995 Mar; 55(6):1261-6. PubMed ID: 7882319
[TBL] [Abstract][Full Text] [Related]
15. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.
Cummings M; Higginbottom K; McGurk CJ; Wong OG; Köberle B; Oliver RT; Masters JR
Biochem Pharmacol; 2006 Jul; 72(2):166-75. PubMed ID: 16756962
[TBL] [Abstract][Full Text] [Related]
16. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
17. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
Gao WM; Romkes M; Day RD; Siegfried JM; Luketich JD; Mady HH; Melhem MF; Keohavong P
Carcinogenesis; 2003 Oct; 24(10):1671-6. PubMed ID: 12844488
[TBL] [Abstract][Full Text] [Related]
18. Common XPD (ERCC2) polymorphisms have no measurable effect on nucleotide excision repair and basal transcription.
Lainé JP; Mocquet V; Bonfanti M; Braun C; Egly JM; Brousset P
DNA Repair (Amst); 2007 Sep; 6(9):1264-70. PubMed ID: 17403617
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of ERCC-2 gene expression in human tumor cell lines by reverse transcription-polymerase chain reaction in comparison to northern blot analysis.
Chen ZP; Malapetsa A; Mohr G; Brien S; Panasci LC
Anal Biochem; 1997 Jan; 244(1):50-4. PubMed ID: 9025907
[TBL] [Abstract][Full Text] [Related]
20. Correlations and co-localizations of Hsp70 with XPA, XPG in human bronchial epithelia cells exposed to benzo[a]pyrene.
Yang J; Liu X; Niu P; Zou Y; Duan Y
Toxicology; 2009 Nov; 265(1-2):10-4. PubMed ID: 19748547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
